检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:袁向珍[1] 刘敏[1] 曹中朝[1] 包秋红[1]
机构地区:[1]内蒙古医科大学附属医院保健中心,呼和浩特010050
出 处:《临床与病理杂志》2015年第1期79-85,共7页Journal of Clinical and Pathological Research
基 金:内蒙古自治区自然科学基金项目(2014MS08113)~~
摘 要:目的:探讨卡维地洛(carvedilol,CAR)对大鼠颈动脉损伤后血管重塑的影响。方法:雄性Wistar大鼠90只,随机分为假手术组、损伤组和CAR组,后两组行颈动脉球囊损伤术。三组均于术后1、3、7、1 4、2 8天处死大鼠。光镜下观察血管损伤后内膜增生情况,用免疫组化和RT-P CR法检测MMP-2、MMP-9和TIMP-1在各组术后不同时间点的表达情况。结果:与损伤组比较,术后14d CAR组内膜面积、内膜与中膜面积比值显著减少,管腔面积显著扩大(P<0.05);与损伤组比较,CAR组术后3-14 d MMP-2、MMP-9表达显著减少(P<0.05),而TIMP-1表达无显著变化(P>0.05)。结论:卡维地洛有效抑制大鼠颈动脉损伤后M MP-2和M MP-9表达,改善了细胞外基质的合成与降解平衡,抑制血管重塑,减轻再狭窄。Objective: To explore the effect of carvedilol (CAR) on vascular remodeling in carotid artery-injured rats. Methods: Ninety Wistar rats were randomly divided into sham-operated group, injury group and CAR group, and the model of carotid balloon injury were established in the latter two groups. The rats were killed on the 1st, 3rd, 7th, 14th, 28th day after injury. The intimal proliferation was observed by optical microscope. The expression of MMP-2, MMP-9 and TIMP-1 at different time points was detected by the method of immunohistochemistry and RT-PCR. Results: The intimal area (LA) and ratio ofintimal and medial area (IA/MA)in CAR group were significantly lower than those in injury group, while lumen area was higher than its in injury group (P〈O.O5). Compared to injury group, the expression of MMP-2 and MMP-9 significantly decreased in CAR group on the 3ra to 14~h day after injury (P〈0.05), while the expression of TIMP-1 had no difference between two groups. Conclusion: CAR could inhibit vascular remodeling and reduce restenosis, the mechanism of which may inhibit the expression of MMP-2 and MMP-9 in carotid artery-injured rats, improve balance of synthesis and degradation ofextracellular matrix.
分 类 号:R543.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145